Page last updated: 2024-10-22

acetaminophen and Budd-Chiari Syndrome

acetaminophen has been researched along with Budd-Chiari Syndrome in 4 studies

Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.
paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.

Budd-Chiari Syndrome: A condition in which the hepatic venous outflow is obstructed anywhere from the small HEPATIC VEINS to the junction of the INFERIOR VENA CAVA and the RIGHT ATRIUM. Usually the blockage is extrahepatic and caused by blood clots (THROMBUS) or fibrous webs. Parenchymal FIBROSIS is uncommon.

Research Excerpts

ExcerptRelevanceReference
" In Europe and North America a large proportion of cases are due to acetaminophen and to idiosyncratic drug reactions, whereas reports from emerging countries in Asia and Africa feature viral illnesses, particularly hepatitis B and E."4.84Etiologies of acute liver failure. ( Lee, WM, 2008)
"To determine the clinical characteristics of patients with acute liver failure of indeterminate cause and their long-term outcome in comparison with patients with acute liver failure of obvious aetiology (acetaminophen and mushroom poisoning, Budd-Chiari syndrome, acute viral hepatitis) and other controls (idiosyncratic drug reactions, autoimmune hepatitis and Wilson's disease)."3.74Long-term follow-up of patients with acute liver failure of indeterminate aetiology. ( Bergquist, A; Björnsson, E; Kalaitzakis, E; Wei, G, 2008)
"The most common causes of ALF were indeterminate liver failure (21%), acute hepatitis B (18%), acetaminophen ingestion (16%), and Budd-Chiari syndrome (9%)."3.74Prognostic implications of lactate, bilirubin, and etiology in German patients with acute liver failure. ( Bahr, MJ; Hadem, J; Klempnauer, J; Manns, MP; Rifai, K; Schneider, AS; Stiefel, P; Tillmann, HL; Wedemeyer, H, 2008)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (75.00)29.6817
2010's1 (25.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Zabron, A1
Quaglia, A1
Fatourou, E1
Peddu, P1
Lewis, D1
Heneghan, M1
Willars, C1
Auzinger, G1
Heaton, N1
Wendon, J1
Kane, P1
Karani, J1
Bernal, W1
Wei, G1
Kalaitzakis, E1
Bergquist, A1
Björnsson, E1
Hadem, J1
Stiefel, P1
Bahr, MJ1
Tillmann, HL1
Rifai, K1
Klempnauer, J1
Wedemeyer, H1
Manns, MP1
Schneider, AS1
Lee, WM1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 2a Study to Evaluate the Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in the Treatment of Patients With Acute Liver Failure/Severe Acute Liver Injury[NCT01548690]Phase 247 participants (Actual)Interventional2012-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Ammonia

To evaluate the effect of OCR-002 on ammonia levels in patients with acute liver failure/severe acute liver injury (NCT01548690)
Timeframe: Baseline and 72 Hours

InterventionPercent Change (Mean)
Maximum Dose Level 3.33 g/24h41.2
Maximum Dose Level 6.65 g/24h16.6
Maximum Dose Level 10 g/24h41.8
Maximum Dose Level 20g/24h38.4

Measurement of OCR-002 Plasma Concentration

To evaluate the steady state pharmacokinetic and pharmacodynamic profile of OCR-002 in patients with impaired and intact renal function using urinary phenylacetylglutamine (PAGN) as a surrogate marker (NCT01548690)
Timeframe: 24 Hours after last infusion

Interventionmicrograms per millileter (Mean)
Maximum Dose Level 3.33 g/24h65.6
Maximum Dose Level 6.65 g/24h32.2
Maximum Dose Level 10 g/24h33.4
Maximum Dose Level 20g/24h104.9

Neurological Function Measured by the Orientation Log (O-log)

The orientation log focuses on orientation to place, time, and circumstance. There are 10 items on the orientation log, which are scored 0-3. A spontaneous correct response is awarded 3 points. A spontaneous response that is lacking or incorrect, but a correct response is provided following a logical cue is awarded 2 points. A score of 1 is given if spontaneous and cued responses are lacking or incorrect, but a correct response is provided in a recognition format. A score of 0 is given if the spontaneous, cued, or recognition format does not generate a correct answer. Scores from the 10 items are summed and the final score ranges from 0 to 30. (NCT01548690)
Timeframe: 30 Days

Interventionunits on a scale (Mean)
Maximum Dose Level 3.33 g/24h23.8
Maximum Dose Level 6.65 g/24h24.0
Maximum Dose Level 10 g/24h24.0
Maximum Dose Level 20g/24h24.0

Neurological Function Measured by the West Haven Criteria (WHC) for Hepatic Encephalopathy

The West Haven Criteria (WHC) for Hepatic Encephalopathy measures the severity of encephalopathy and patient's level of consciousness. The scale ranges from 0 to 4; a minimum score of 0 represents a better outcome, and a maximum total score of 4 represents a worse outcome. A score of 0 corresponds to normal consciousness and behavior and normal neurological examination. A score of 1 corresponds to mild lack of awareness, shortened attention span, and impaired addition or subtraction; mild asterixis or tremor. A score of 2 corresponds to lethargy, disorientated or inappropriate behavior, obvious asterixis; slurred speech. A score of 3 corresponds to somnolent but arousable, gross disorientation or bizarre behavior, muscle rigidity and clonus; hyperreflexia. A score of 4 corresponds to coma and decerebrate posturing. (NCT01548690)
Timeframe: 120 hours from start of infusion

Interventionunits on a scale (Mean)
Maximum Dose Level 3.33 g/24h2.4
Maximum Dose Level 6.65 g/24h3.2
Maximum Dose Level 10 g/24h1.6
Maximum Dose Level 20g/24h1.8

Number of Participants That do Not Tolerate the Administered Dose and Had Grade 3 or 4 Treatment Emergent Adverse Events as a Measure of Safety and Tolerability

To evaluate the safety and tolerability of OCR-002 in patients with acute liver failure/severe acute liver injury (NCT01548690)
Timeframe: 30 Days

InterventionParticipants (Count of Participants)
Maximum Dose Level 3.33 g/24h0
Maximum Dose Level 6.65 g/24h0
Maximum Dose Level 10 g/24h0
Maximum Dose Level 20g/24h0

Reviews

1 review available for acetaminophen and Budd-Chiari Syndrome

ArticleYear
Etiologies of acute liver failure.
    Seminars in liver disease, 2008, Volume: 28, Issue:2

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Budd-Chiari Syndrome; Drug-Related Side Effects and Adverse

2008

Other Studies

3 other studies available for acetaminophen and Budd-Chiari Syndrome

ArticleYear
Clinical and prognostic associations of liver volume determined by computed tomography in acute liver failure.
    Liver international : official journal of the International Association for the Study of the Liver, 2018, Volume: 38, Issue:9

    Topics: Acetaminophen; Adult; Budd-Chiari Syndrome; Decision Support Techniques; Disease Progression; Female

2018
Long-term follow-up of patients with acute liver failure of indeterminate aetiology.
    Scandinavian journal of gastroenterology, 2008, Volume: 43, Issue:8

    Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Budd-Chiari Syndrome; Disease Progression; Female; F

2008
Prognostic implications of lactate, bilirubin, and etiology in German patients with acute liver failure.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2008, Volume: 6, Issue:3

    Topics: Acetaminophen; Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Bilirubin; Biomarkers; Budd-Chiari

2008